Effect of pretreatment with low-dose Esketamine on myoclonus induced by etomidate

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300074192

Enrollment

Unknown

Registered

2023-08-01

Start date

2023-08-01

Completion date

Unknown

Last updated

2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing general anesthesia surgery

Interventions

Group EK :Pretreat with esketamine

Group C:receive placebo

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients undergoing elective general anesthesia surgery; (2) ASA is classified as Grade I-III; (3) Age 18-65 years; (4) Voluntary subjects signed an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Pregnant patients (2) Patients with adrenal cortical insufficiency (3) Patients with neurological disorders and mental disorders (4) Patients who are allergic to the study drug (5) Patients who have taken pain relievers, sedatives, or opioids within the past 24 hours (6) Obesity (BMI>30kg/m2) (7) Patients with difficult airways (8) Severe liver or renal insufficiency (9) Patients with severe cardiovascular disease (10) full stomach

Design outcomes

Primary

Measure	Time frame
Intensity of myoclonus after injection of etomidate;The degree of myoclonus;	—

Secondary

Measure	Time frame
Adverse reactions;vital signs;	—

Countries

China

Contacts

Public ContactLijian Chen

The First Affiliated Hospital of Anhui Medical University

chenlijian77@126.com+86 139 6669 9467

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026